AI assistant
Sending…
Q32 Bio Inc. — Director's Dealing 2023
Jan 20, 2023
34891_dirs_2023-01-20_6c72df5a-b8a3-47b2-96b3-f021728ce505.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4/A — Form 4/A
Issuer: Homology Medicines, Inc. (FIXX)
CIK: 0001661998
Period of Report: 2023-01-09
Reporting Person: Alloway Paul (See Remarks)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 16706 | Direct |
Footnotes
F1: This amended Form 4 is being filed to correct the aggregate common stock holdings of the Reporting Person. On each of January 4, 2023 and January 11, 2023, the Reporting Person filed a Form 4 that inadvertently re-reported Employee Stock Purchase Plan ("ESPP") shares that were previously reported. Accordingly, the common stock holdings in column 5 of Table I have been reduced by 3,397 ESPP shares.
More from Q32 Bio Inc.
Capital/Financing Update
2026
May 27
Interim / Quarterly Report
2026
May 5
Earnings Release
2026
May 5
Annual Report
2026
Apr 30
Proxy Solicitation & Information Statement
2026
Apr 30
Capital/Financing Update
2026
Apr 24
Director's Dealing
2026
Mar 21
Director's Dealing
2026
Mar 21
Director's Dealing
2026
Mar 21
Director's Dealing
2026
Feb 27